Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free NDRA Stock Alerts

ENDRA Life Sciences (NDRA) Competitors

ENDRA Life Sciences logo
$4.68 +0.25 (+5.52%)
As of 10:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NDRA vs. RVP, LFWD, IRIX, TMDIF, and CODX

Should you buy ENDRA Life Sciences stock or one of its competitors? MarketBeat compares ENDRA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ENDRA Life Sciences include Retractable Technologies (RVP), Lifeward (LFWD), IRIDEX (IRIX), Titan Medical (TMDIF), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.

How does ENDRA Life Sciences compare to Retractable Technologies?

ENDRA Life Sciences (NASDAQ:NDRA) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

ENDRA Life Sciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 433.62%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe ENDRA Life Sciences is more favorable than Retractable Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Retractable Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 0 mentions for Retractable Technologies. ENDRA Life Sciences' average media sentiment score of 1.43 beat Retractable Technologies' score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Positive
Retractable Technologies Neutral

Retractable Technologies has higher revenue and earnings than ENDRA Life Sciences. Retractable Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Retractable Technologies$37.15M0.56-$7.01M-$0.21N/A

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 59.5% of Retractable Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Retractable Technologies' return on equity of -17.15% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Retractable Technologies -41.11%-17.15%-9.33%

Summary

Retractable Technologies beats ENDRA Life Sciences on 8 of the 15 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Lifeward?

ENDRA Life Sciences (NASDAQ:NDRA) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

ENDRA Life Sciences has higher earnings, but lower revenue than Lifeward. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Lifeward$22.03M0.90-$19.91M-$19.66N/A

ENDRA Life Sciences presently has a consensus price target of $25.00, suggesting a potential upside of 433.62%. Lifeward has a consensus price target of $10.00, suggesting a potential upside of 42.25%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe ENDRA Life Sciences is more favorable than Lifeward.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lifeward
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

ENDRA Life Sciences has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Lifeward -123.66%-243.14%-97.39%

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ENDRA Life Sciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 2 articles in the media. ENDRA Life Sciences' average media sentiment score of 1.43 beat Lifeward's score of 1.33 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Positive
Lifeward Positive

Summary

ENDRA Life Sciences beats Lifeward on 7 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$52.67M0.37-$4.44M-$0.19N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

IRIDEX has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

In the previous week, IRIDEX had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 3 mentions for IRIDEX and 2 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.43 beat IRIDEX's score of 0.87 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
IRIDEX Positive
ENDRA Life Sciences Positive

IRIDEX currently has a consensus target price of $3.00, suggesting a potential upside of 165.25%. ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 433.62%. Given ENDRA Life Sciences' higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than IRIDEX.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%. ENDRA Life Sciences' return on equity of -433.64% beat IRIDEX's return on equity.

Company Net Margins Return on Equity Return on Assets
IRIDEX-6.23% -1,204.74% -11.16%
ENDRA Life Sciences N/A -433.64%-204.58%

Summary

IRIDEX beats ENDRA Life Sciences on 7 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 433.62%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Titan Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Titan Medical has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Medical$17.63M1.10$6.95M$0.053.40
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 0 mentions for Titan Medical. ENDRA Life Sciences' average media sentiment score of 1.43 beat Titan Medical's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Titan Medical Neutral
ENDRA Life Sciences Positive

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Titan Medical's return on equity of -82.31% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Titan MedicalN/A -82.31% -51.47%
ENDRA Life Sciences N/A -433.64%-204.58%

Summary

Titan Medical and ENDRA Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Co-Diagnostics?

ENDRA Life Sciences (NASDAQ:NDRA) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Co-Diagnostics had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 3 mentions for Co-Diagnostics and 2 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.43 beat Co-Diagnostics' score of 0.30 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Positive
Co-Diagnostics Neutral

ENDRA Life Sciences has higher earnings, but lower revenue than Co-Diagnostics. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Co-Diagnostics$620K23.51-$46.90M-$15.77N/A

ENDRA Life Sciences has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Co-Diagnostics -6,760.63%-164.92%-141.15%

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 433.62%. Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 1,608.86%. Given Co-Diagnostics' higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than ENDRA Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Co-Diagnostics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

ENDRA Life Sciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the broader market.

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Co-Diagnostics beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NDRA vs. The Competition

Export
MetricENDRA Life SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$5.95M$7.10B$6.49B$12.31B
Dividend YieldN/A1.21%2.67%5.66%
P/E Ratio-0.5748.6624.0524.76
Price / SalesN/A83.85542.61168.32
Price / CashN/A25.5927.4837.92
Price / Book2.446.9510.696.90
Net Income-$7.03M$159.20M$3.57B$337.45M
7 Day Performance9.72%0.12%1.56%2.84%
1 Month Performance-7.23%6.17%2.49%4.78%
1 Year Performance35.80%3.22%26.51%33.08%

ENDRA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NDRA
ENDRA Life Sciences
3.3882 of 5 stars		$4.69
+5.5%		$25.00
+433.6%		+32.2%$5.95MN/AN/A20
RVP
Retractable Technologies
N/A$0.69
+0.2%		N/A+7.5%$20.60M$37.15MN/A240
LFWD
Lifeward
3.0805 of 5 stars		$6.98
flat		$10.00
+43.3%		-48.6%$19.65M$22.03MN/A60
IRIX
IRIDEX
2.3977 of 5 stars		$1.12
+0.9%		$3.00
+167.9%		+19.1%$19.32M$52.67MN/A120
TMDIF
Titan Medical
N/A$0.17
-3.8%		N/A-34.3%$19.19M$17.63MN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel